Powered by HealthTechMovers.com
We added 3 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
DENTSPLY SIRONA, XRAY
Summary: DENTSPLY SIRONA Inc. is a global leader in the design, development, manufacture and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products. In addition, it provides dental technology products, including dental implants and related scanning equipment, treatment software, and orthodontic appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. The business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.
- Last Price: $31.32
- Price Change: -$0.04, -0.13%
- Yearly Gain: 4.43%
- Market Cap: $6.64B
- P/E Ratio: -30.991
Here are 3rd party ratings for XRAY:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Bottom 37% (158 out of 251)
What is the sentiment on the street regarding DENTSPLY SIRONA ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in XRAY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on XRAY before you decide to make any investment.
Click here for chart >>
ImmunoGen, IMGN
Summary: ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla and in development programs of its partners Bayer, Biotest, CytomX, Novartis, Sanofi, Roche, Takeda, Debiopharm & Jazz Pharmaceuticals.'Among ImmunoGen's wholly owned candidates, mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, is being developed as a single-agent therapy for platinum-resistant ovarian cancer and in combination regimens for both platinum-resistant and platinum-sensitive disease. The candidate is also being developed in combination with other cancer drugs in a mid-stage study.'Pivekimab sunirine is currently under evaluation in early- to mid-stage studies for treatment of patients with acute myeloid leukemia & other CD123-positive hematological malignancies.
- Last Price: $16.06
- Price Change: -$0.08, -0.5%
- Yearly Gain: 211.84%
- Market Cap: $4.28B
- P/E Ratio: -53.604
Here are 3rd party ratings for IMGN:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Buy, Top 24% (59 out of 251)
What is the sentiment on the street regarding ImmunoGen ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Neutral
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in IMGN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on IMGN before you decide to make any investment.
Click here for chart >>
Repare Therapeutics, RPTX
Summary: Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.
- Last Price: $5.05
- Price Change: $0.17, 3.48%
- Yearly Gain: -68.55%
- Market Cap: $212.75M
- P/E Ratio: -2.18
Here are 3rd party ratings for RPTX:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 17% (43 out of 251)
What is the sentiment on the street regarding Repare Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in RPTX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on RPTX before you decide to make any investment.
Click here for chart >>
Thanks for reading!
